EVH trades 42.1% below Wall Street's consensus target of $6.38.
Last 12 months price action with 12-month analyst target path
The base valuation assumes EVH achieves its forward estimates and maintains a stable P/E multiple of 24.8x. This scenario reflects the blended consensus of 29 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Evolent Health, Inc. (EVH) has a Wall Street consensus price target of $6.38, based on estimates from 29 covering analysts. With the stock currently trading at $4.49, this represents a potential upside of +42.1%. The company has a market capitalization of $505M.
Analyst price targets range from a low of $3.50 to a high of $10.00, representing a 102% spread in expectations. The median target of $6.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 23 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, EVH trades at a trailing P/E of -0.9x and forward P/E of 24.8x. Analysts expect EPS to grow +104.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
PINCPremier, Inc. | $2.3B | $28.26 | $33.15 | +17.3% | Hold | 20.8x | 31 |
ALHCAlignment Healthcare, Inc. | $4.5B | $21.86 | $24.33 | +11.3% | Buy | 118.7x | 16 |
HQYHealthEquity, Inc. | $7.1B | $85.21 | $107.33 | +26.0% | Buy | 21.5x | 27 |
TDOCTeladoc Health, Inc. | $1.5B | $8.07 | $7.40 | -8.3% | Hold | — | 42 |
OSCROscar Health, Inc. | $7.4B | $28.40 | $24.20 | -14.8% | Hold | 31.5x | 11 |
CLOVClover Health Investments, Corp. | $2.6B | $5.00 | $4.47 | -10.6% | Hold | 129.2x | 9 |
HIMSHims & Hers Health, Inc. | $7.8B | $35.47 | $28.08 | -20.8% | Hold | — | 20 |
DOCSDoximity, Inc. | $3.8B | $20.46 | $29.47 | +44.0% | Hold | 14.3x | 23 |
UNHUnitedHealth Group Incorporated | $363.9B | $400.96 | $425.81 | +6.2% | Buy | 21.8x | 52 |
CVSCVS Health Corporation | $125.4B | $98.32 | $103.64 | +5.4% | Buy | 13.3x | 41 |
Quick answers to the most common questions about buying EVH stock.
The consensus Wall Street price target for EVH is $6.38, representing 42.1% upside from the current price of $4.49. With 29 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
EVH has a consensus rating of "Buy" based on 29 Wall Street analysts. The rating breakdown is predominantly bullish, with 23 Buy/Strong Buy ratings. The consensus 12-month price target of $6.38 implies 42.1% upside from current levels.
EVH trades at a forward P/E of 24.7792x, representing a moderate valuation. With analysts targeting $6.38 (42.1% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $10 for EVH, while the most conservative target is $3.5. The consensus of $6.38 represents the median expectation. These targets typically reflect 12-month expectations.
EVH is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 23 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month EVH stock forecast based on 29 Wall Street analysts shows a consensus price target of $6.38, with estimates ranging from $3.5 (bear case) to $10 (bull case). The median consensus rating is "Buy".
EVH trades at a forward P/E ratio of 24.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on EVH, with a "Buy" consensus rating and $6.38 price target (42.1% upside). 23 of 29 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
EVH analyst price targets range from $3.5 to $10, a 102% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6.38 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.